Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0H2YY
|
|||
| Former ID |
DNCL002227
|
|||
| Drug Name |
JX-929
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 1 | [1] | |
| Company |
Jennerex Biotherapeutics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cytosine deaminase (AICDA) | Target Info | Modulator | [2] |
| KEGG Pathway | Intestinal immune network for IgA production | |||
| Primary immunodeficiency | ||||
| NetPath Pathway | IL4 Signaling Pathway | |||
| ID Signaling Pathway | ||||
| Pathway Interaction Database | IL4-mediated signaling events | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00574977) Safety Study of Modified Vaccinia Virus to Cancer. U.S. National Institutes of Health. | |||
| REF 2 | Micromanaging oncolytic viruses. SciBX 1(42); doi:10.1038/scibx.2008.1014. Nov. 20 2008 | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.